NCT03292055

Brief Summary

This study aims to evaluate the psychometric properties of a newly developed FFQ specified for northern Chinese CHD and their high risk patients (CHD-FFQ). The psychometric properties include test-retest reliability, content validity, convergent validity, discriminant validity, concurrent validity and predictive validity. Particularly, this study will measure the physiological indicators, including plasma lipid profile (i.e. TG, TC, HDL-C, LDL-C), BG, BP and BMI twice at baseline and the end. The level of these physiological indicators will be compared with the fat intake measured by the CHD-FFQ, i.e. the baseline intake to test its convergent validity. It is also expected to predict the diet-related progression of CHD risks among high-risk individuals, i.e. patients with two or more CHD risk factors as following: raised fasting blood glucose (BG) level, increased blood pressure (BP), increased triglycerides (TG), decreased HDL-Cholesterol (HDL-C), increased LDL-Cholesterol (LDL-C), smoking and central obesity (International Diabetes Federation, 2015). In addition, this study will provide the FFQ's concurrent validity in assessing the intake of energy and nutrients against the CDC-FFQ. Moreover, whether the FFQ could detect the known differences in energy intake between men and women will be established for its discriminant validity.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
235

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2017

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 13, 2017

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

September 19, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 25, 2017

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2017

Completed
Last Updated

January 25, 2018

Status Verified

January 1, 2018

Enrollment Period

11 months

First QC Date

September 19, 2017

Last Update Submit

January 23, 2018

Conditions

Keywords

food frequency questionnaire; psychometric properties

Outcome Measures

Primary Outcomes (8)

  • Intake of Food

    The newly developed FFQ (CHD-FFQ) will be applied to the participants to collect their dietary intake of food.

    January-February, April- May, July- August, October- November

  • Cardiac-related physiological blood parameters

    In the beginning and the end of the study, the medical records of the participants will be refered to get the blood glucose, total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in the past three months, in the department and the community centers.

    January- February, October- November

  • Height

    Participant's height will be measured to the nearest 0.5 cm, with a right-angle triangle resting on the scalp and against the wall, having the back square against the wall tape and eyes looking straight ahead. The height will be measured without wearing shoes.

    January-February, April- May, July- August, October- November

  • Weight

    A calibrated scale with the resolution of 0.1 kg will be used to measure the weight of the participants, who will be asked to wear light clothes during measurement. The weight will be measured without shoes.

    January-February, April- May, July- August, October- November

  • BMI

    weight and height will be combined to report BMI in kg/m\^2

    January-February, April- May, July- August, October- November

  • Waist circumstance

    Waist circumstance will be taken at the midpoint between the top of the iliac crest and the lower margin of the palpable rib

    January-February, April- May, July- August, October- November

  • Blood pressure

    To take the blood pressure, the participant will be asked to be seated for at least 15 minutes with his/her legs uncrossed (WHO, 2008). Two BP measurements will be taken and between the two readings, the participant will have three minutes' rest.

    January-February, April- May, July- August, October- November

  • Intake of Food

    As a criterion, the FFQ developed by Chinese CDC will be applied to the participants to collect their dietary intake of food.

    October-November

Secondary Outcomes (4)

  • Sociodemographic information

    January-February

  • General clinical information

    January-February

  • Clinical Information

    October- November

  • Physical activity level

    January-February, April- May, July- August, October- November

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

CHD high-risk patients (corresponding to the inclusion criteria)

You may qualify if:

  • years or older;
  • Have no CHD at enrollment;
  • At high risk of CHD with at least two of the following risk factors:
  • current smoking: current smokers are defined as individuals who smoked regularly during the last 12 months
  • central obesity: for Chinese, central obesity is defined as waist circumstance above 90cm for male and 80cm for female, or with BMI above 30kg/m²
  • raised BP (systolic BP \[SBP\] ≥ 130 mmHg or diastolic BP \[DBP\] ≥85 mmHg or under antihypertensive treatment)
  • raised fasting BG (FBG) (100mg/dL \[5.6mmol/L\]) or under treatment with insulin or oral hypoglycemic agents
  • elevated TG (150mg/dL \[1.7mmol/L\])
  • elevated TC (≥ 240 mg/dL \[5.18 mmol/L\])
  • raised LDL-C (≥ 160 mg/dL \[4.15 mmol/L\])
  • decreased HDL-C (\<40 mg/dL \[1.03 mmol/L\] for males, and \<50 mg/dL \[1.29 mmol/L\] for females)
  • undergoing hyperlipidemia treatment

You may not qualify if:

  • Impaired bilateral hearing
  • Impaired mental status (according to their medical record)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Qilu Hospital

Jinan, Shandong, 250012, China

Location

Jinan Central Hospital

Jinan, Shandong, 250013, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood testing for the blood glucose, lipid profile

MeSH Terms

Conditions

Coronary Disease

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular Diseases

Study Officials

  • SekYing CHAIR, PHD

    Chinese University of Hong Kong

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Graduate Assistant

Study Record Dates

First Submitted

September 19, 2017

First Posted

September 25, 2017

Study Start

January 13, 2017

Primary Completion

December 15, 2017

Study Completion

December 15, 2017

Last Updated

January 25, 2018

Record last verified: 2018-01

Data Sharing

IPD Sharing
Will not share

All questionnaires and other collected data will be stored in a locked file cabinet, and no names or other personal data of participants will be used in publication. Only the PI and her supervisor will have access to these data.

Locations